JP2010111645A - Skin-lightening agent and skin cosmetic product - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a skin-lightening agent and a skin cosmetic product obtained by finding a substance having skin-whitening action from natural materials and using the substance as an active component. <P>SOLUTION: The skin-lightening agent contains an extract of Vitis ficifolia or one or more kinds of polyphenol compounds selected from ε-viniferin, ampelopsin A and ampelopsin C. The skin cosmetic product contains the extract of Vitis ficifolia or one or more of polyphenol compounds selected from ε-viniferin, ampelopsin A and ampelopsin C. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to a whitening agent and a skin cosmetic containing a naturally derived ingredient as an active ingredient.

  Melanin also plays a role in protecting the body from ultraviolet rays in the skin, but overproduction and uneven accumulation cause skin darkening and spots. In general, melanin is converted from tyrosine to dopa and from dopa to dopaquinone by the action of the enzyme tyrosinase biosynthesized in pigment cells, and then formed through intermediates such as 5,6-dihydroxyindophenol. ing. Therefore, in order to prevent, treat or improve skin darkness (skin pigmentation), it is conceivable to inhibit the activity of tyrosinase involved in the production of melanin or to suppress the production of melanin.

Conventionally, for the prevention, treatment or improvement of skin pigmentation, stains, buckwheat, etc., a treatment using a whitening agent containing a chemically synthesized product such as hydroquinone as an active ingredient has been performed. However, chemically synthesized products such as hydroquinone may cause side effects such as skin irritation and allergy. Therefore, development of a whitening agent comprising a highly safe natural raw material as an active ingredient is desired. Examples of those having a tyrosinase activity inhibitory action belong to, for example, mulberry leaf extract (see Patent Document 1), Southurea genus Plant extract (see patent document 2), Fuji tea extract (see patent document 3), willow tree extract (see patent document 4), bamboo shoot and licorice root extract (see patent document 5), mango ginger extract ( Patent Document 6) is known. Moreover, as what has a melanin production inhibitory effect, the extract (refer patent document 7) from a castor bean root part, the extract (refer patent document 8) from the plant which belongs to the South urea (Saussurea) genus, etc. are known, for example. Yes.
Japanese Patent Laid-Open No. 11-246424 JP 2002-201222 A JP 2002-370962 A JP 2004-83488 A JP 2004-352697 A JP 2005-104886 A JP 2001-213757 A JP 2002-201222 A

  An object of the present invention is to find a natural product having a tyrosinase activity inhibitory action and / or a melanin production inhibitory action, and to provide a whitening agent and a skin cosmetic containing the same as an active ingredient.

  In order to achieve the above object, firstly, the whitening agent of the present invention is an extract from shrimp, or one or more polyphenol compounds selected from the group consisting of ε-viniferin, amperopsin A and amperopsin C. Is contained as an active ingredient.

  Secondly, the skin cosmetic of the present invention is characterized by blending an extract from shrimp, or one or more polyphenol compounds selected from the group consisting of ε-viniferin, amperopsin A and amperopsin C. To do.

  According to the present invention, an extract from shrimp having excellent tyrosinase activity inhibitory action and / or melanin production inhibitory action, or one or more kinds selected from the group consisting of ε-viniferin, amperopsin A and amperopsin C A whitening agent and a skin cosmetic containing a polyphenol compound as an active ingredient can be provided.

The present invention will be described below.
[Whitening agent]
The whitening agent of the present invention is an extract from shrimp or one or more polyphenols selected from the group consisting of ε-viniferin, amperopsin A and amperopsin C represented by the following formulas (1) to (3) A compound is contained as an active ingredient.

  Here, in the present invention, the “extract from shrimp” refers to an extract obtained from shrimp as an extraction raw material, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or these Both of these crudely purified products and purified products are included.

  The polyphenol compounds represented by the above formulas (1) to (3) (ε-viniferin, amperopsin A or amperopsin C) can be produced by isolating and purifying from plant extracts containing them. It can also be produced by synthesis. In addition, when manufacturing by a synthesis | combination, the synthesis | combining method is not specifically limited, It can synthesize | combine by a well-known method.

  The plant extract containing the polyphenol compound can be obtained by an extraction method generally used for plant extraction. As a plant containing the said compound, a shrimp (scientific name: Vitis ficifolia) is mentioned, for example.

  Shrimp (Vitis ficifolia) is a woody vine belonging to the genus Grapeaceae distributed in Honshu, Shikoku, Kyushu, etc., and can be easily obtained from these regions. Examples of the part that can be used as an extraction raw material include a leaf part, a stem part, a vine part, a seed part, a fruit part, a flower part, an above-ground part, a root part, or a mixture of these parts. It is.

  The extract from shrimp can be obtained by drying the shrimp, pulverizing it as it is or using a crusher, and subjecting it to extraction with an extraction solvent. Drying may be performed in the sun or using a commonly used dryer. Moreover, after performing pretreatment, such as degreasing, with a nonpolar solvent such as hexane, it may be used as an extraction raw material. By performing pretreatment such as degreasing, extraction with a polar solvent can be performed efficiently.

  As the extraction solvent, it is preferable to use a polar solvent, and examples thereof include water and hydrophilic organic solvents. These are used alone or in combination of two or more at room temperature or a temperature below the boiling point of the solvent. It is preferable.

  Examples of water that can be used as the extraction solvent include pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, and those subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, and the like. Therefore, the water that can be used as the extraction solvent in the present invention includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.

  Examples of hydrophilic organic solvents that can be used as extraction solvents include lower aliphatic alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene. Examples thereof include polyhydric alcohols having 2 to 5 carbon atoms such as glycol, propylene glycol and glycerin.

  When using the liquid mixture of 2 or more types of polar solvents as an extraction solvent, the mixing ratio can be adjusted suitably. For example, when using a liquid mixture of water and a lower aliphatic alcohol, it is preferable to mix 1 to 90 parts by weight of a lower aliphatic alcohol with respect to 10 parts by weight of water. When using a mixed solution, it is preferable to mix 1 to 40 parts by mass of a lower aliphatic ketone with 10 parts by mass of water, and when using a mixed solution of water and a polyhydric alcohol, water 10 It is preferable to mix 1-90 mass parts of polyhydric alcohol with respect to mass parts.

  The extraction treatment is not particularly limited as long as the soluble component contained in the extraction raw material can be eluted in the extraction solvent, and can be performed according to a conventional method. For example, the extraction raw material is immersed in an extraction solvent 5 to 15 times (mass ratio) of the extraction raw material, the soluble components are extracted at room temperature or under reflux, and then filtered to remove the extraction residue. A liquid can be obtained. When the solvent is distilled off from the obtained extract, a paste-like concentrate is obtained, and when this concentrate is further dried, a dried product is obtained.

  The method for isolating and purifying the polyphenol compounds from the extract obtained as described above, the concentrate of the extract or the dried product of the extract is not particularly limited, and is performed by a conventional method. be able to. For example, the extract from shrimp is concentrated and subjected to liquid-liquid partition extraction, ion exchange resin, column chromatography using a porous resin (for example, silica gel), and the eluate is collected about every 1 hour. . The polyphenol compounds can be isolated and purified by subjecting the eluate thus collected to further fractionation by high-performance liquid chromatography or the like, and crystallization as necessary.

  Since the extract from shrimp obtained as described above or the polyphenol compound has a whitening action, it can be used as an active ingredient of a whitening agent by utilizing the whitening action.

  The whitening action of the extract from shrimp or the polyphenol compound is exhibited based on, for example, a tyrosinase activity inhibitory action and / or a melanin production inhibitory action. However, the whitening action of the extract from shrimp or the polyphenol compound is not limited to the whitening action exhibited based on these actions. In addition, since the extract from shrimp or the polyphenol compound has a tyrosinase activity inhibitory action or a melanin production inhibitory action, it is used as an active ingredient of a tyrosinase activity inhibitor or a melanin production inhibitor using these actions. You can also.

  In the present invention, any one polyphenol compound of ε-viniferin, amperopsin A and amperopsin C may be used as the active ingredient, and two or more polyphenol compounds among them may be used. You may mix and use as said active ingredient. In addition, an extract from shrimp and at least one polyphenol compound of ε-viniferin, amperopsin A and amperopsin C may be mixed and used as the active ingredient. When two or more kinds of polyphenol compounds among ε-viniferin, amperopsin A and amperopsin C are mixed and used as the active ingredient, or an extract from shrimp and ε-viniferin, amperopsin A and amperopsin C When at least one polyphenol compound is mixed and used as the active ingredient, the blending ratio may be appropriately determined according to the degree of their action.

  The whitening agent of the present invention may be composed only of an extract from shrimp or the above polyphenol compound, or may be a product obtained by formulating an extract from shrimp or the above polyphenol compound.

  The extract from shrimp or the above polyphenol compounds can be used in the form of powder, granules, liquids, etc. according to a conventional method using a pharmaceutically acceptable carrier such as dextrin and cyclodextrin and any other auxiliary agent. It can be formulated into a dosage form. In this case, as an auxiliary agent, for example, an excipient, a binder, a disintegrant, a lubricant, a stabilizer, a flavoring agent and the like can be used. In addition, the extract from shrimp or the above polyphenol compound can be used by blending with other compositions (for example, skin cosmetics described later), as an ointment, a liquid for external use, a patch, etc. Can be used.

  In addition, the whitening agent of this invention can mix | blend the other natural extract which has a whitening effect | action as needed, and can use it as an active ingredient.

  The whitening agent of the present invention prevents skin darkening, spots, freckles, etc. through the whitening action (for example, tyrosinase activity inhibitory action, melanin production inhibitory action, etc.) possessed by the extract from shrimp or the polyphenol compounds, Can be treated or improved. However, the whitening agent of the present invention can be used for all uses other than these uses, which are meaningful for exerting a whitening effect.

[Skin cosmetic]
The extract from shrimp or the above polyphenol compound is excellent in usability and safety when applied to the skin, and is therefore suitable for blending into skin cosmetics. In this case, an extract from shrimp or the above polyphenol compound may be blended, or a whitening agent formulated from an extract from shrimp or the above polyphenol compound may be blended. A whitening action can be imparted to the skin cosmetic by blending the extract from shrimp, the polyphenol compound or the whitening agent into the skin cosmetic.

  The skin cosmetics that can be blended with the extract from shrimp, the polyphenol compound or the whitening agent are not particularly limited. For example, ointments, creams, emulsions, lotions, packs, foundations, lip balms, bathing agents , Hair nick, hair lotion, soap, body shampoo, etc.

  When the extract from shrimp, the polyphenol compound or the whitening agent is blended in the skin cosmetic, the blending amount can be adjusted as appropriate according to the type of the skin cosmetic. It is about 0.0001 to 10% by mass in terms of a standard extract, and a particularly suitable blending ratio is about 0.001 to 1% by mass in terms of a standard extract.

  The skin cosmetic of the present invention is a main agent, auxiliary agent or other component used in the production of ordinary skin cosmetics, for example, an astringent, as long as it does not interfere with the whitening action of the extract from shrimp or the polyphenol compound. , Disinfectant / antibacterial agent, whitening agent, UV absorber, moisturizer, cell activator, anti-inflammatory / antiallergic agent, antioxidant / active oxygen remover, fats and oils, waxes, hydrocarbons, fatty acids, alcohols, Esters, surfactants, fragrances and the like can be used in combination. When used in combination, it becomes a more general product, and a synergistic effect with other active ingredients used in combination may lead to an excellent effect that is more than normally expected.

  In addition, although the whitening agent or skin cosmetics of this invention are suitably applied with respect to a human, as long as each effect is show | played, it can also apply to animals other than a human.

  Hereinafter, although a manufacture example, a test example, and a compounding example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to each following example at all.

[Production Example 1] Production of shrimp extract A vine portion of dried shrimp is pulverized, 1000 mL of an extraction solvent is added to 100 g of the pulverized product, and heated and extracted at 80 ° C for 3 hours with gentle stirring. Filtered hot. The filtrate was concentrated under reduced pressure at 40 ° C., and further dried with a vacuum dryer to obtain shrimp extract (samples 1 to 3). Table 1 shows the yield (g) of each extract when water, 50% by volume ethanol (volume ratio of water to ethanol = 1: 1), and ethanol were used as the extraction solvent.

[Production Example 2] Production of ε-viniferin, amperopsin A and amperopsin C 5.7 g of shrimp vine ethanol extract (sample 3) obtained in Production Example 1 was mixed with chloroform: methanol: water = 10: 3: 1 ( (Volume ratio) was dissolved in a mixed solvent, and was introduced from the top of a glass column packed with silica gel (trade name: silica gel 60, manufactured by Merck & Co., Inc.) and adsorbed onto silica gel.

  As a mobile phase, a mixed solvent of chloroform: methanol: water = 10: 3: 1 (volume ratio) was injected from the top of the column, and the eluate was collected after 1 hour, and the solvent was removed. 1 (312 mg), fraction 2 (715 mg) and fraction 3 (933 mg) were obtained.

  Fraction 1 obtained as described above was fractionated using the following high performance liquid chromatography condition 1 recycle HPLC to obtain a crude product 1 and then high performance liquid chromatography condition 2 recycle HPLC. To obtain purified product 1 (149 mg).

<High performance liquid chromatography condition 1>
Stationary phase: two JAIGEL GS-310 (manufactured by Nippon Analytical Industrial Co., Ltd.) connected Column diameter: 20 mm
Column length: 500mm (250mm x 2)
Mobile phase: Methanol Mobile phase flow rate: 5 mL / min
Detection: RI

<High performance liquid chromatography condition 2>
Stationary phase: YMC-Pack ODS-A (manufactured by YMC)
Column diameter: 20mm
Column length: 250mm
Mobile phase: acetonitrile: water = 2: 5
Mobile phase flow rate: 9 mL / min
Detection: RI

  In addition, fraction 2 obtained as described above was fractionated using the following high-performance liquid chromatography condition 3 recycle HPLC to obtain a crude product 2, and then high-performance liquid chromatography condition 4 recycle HPLC To give purified product 2 (715 mg).

<High performance liquid chromatography condition 3>
Stationary phase: YMC-Pack ODS-A (manufactured by YMC)
Column diameter: 20mm
Column length: 250mm
Mobile phase: acetonitrile: water = 3: 10
Mobile phase flow rate: 9 mL / min
Detection: RI

<High performance liquid chromatography condition 4>
Stationary phase: two JAIGEL GS-310 (manufactured by Nippon Analytical Industrial Co., Ltd.) connected Column diameter: 20 mm
Column length: 500mm (250mm x 2)
Mobile phase: Methanol Mobile phase flow rate: 5 mL / min
Detection: RI

  Furthermore, fraction 3 obtained as described above was fractionated using a recycle HPLC under the following high performance liquid chromatography condition 5 to obtain purified product 3 (111 mg).

The results of analyzing each purified product (purified products 1 to 3) obtained as described above by ESI-mass spectrum and ¹³ C-NMR are shown below.

<ESI-mass spectrum of purified product 1>
m / z 455 (M + H) ⁺

< ¹³ C-NMR chemical shift δ (assigned carbon) of the purified product 1:>
162.5 (3-C), 159.8 (11'-C), 159.6 (13'-C), 158.2 (12-C, 4'-C), 147.4 (9'-C), 136.4 (1-C), 133.9 (1'-C), 130.1 (8-C), 129.9 (9-C), 128.7 (10-C, 14-C), 127.9 (2'-C, 6'-C), 123.5 (7- C), 119.8 (2-C), 116.3 (11-C, 13-C), 116.1 (3'-C, 5'-C), 107.0 (10'-C, 14'-C), 104.2 (6 -C), 102.1 (12'-C), 96.8 (4-C), 93.9 (7'-C), 57.1 (8'-C)

<ESI-mass spectrum of purified product 2>
m / z 471 (M + H) ⁺

< ¹³ C-NMR chemical shift δ (assigned carbon) of purified product 2:>
160.1 (11-C), 159.9 (13-C, 13'-C), 158.5 (4-C), 157.3 (4'-C), 156.1 (11'-C), 143.0 (9'-C), 140.3 (9-C), 132.6 (1'-C), 130.9 (1-C), 129.9 (2'-C, 6'-C), 118.3 (10-C), 116.2 (10'-C), 116.0 (3'-C, 5'-C), 115.4 (3-C, 5-C), 110.5 (14-C), 105.5 (14'-C), 101.6 (12'-C), 97.1 (12 -C), 88.4 (7'-C), 71.2 (8-C), 49.5 (8'-C), 43.9 (7-C)

<ESI-mass spectrum of purified product 3>
m / z 681 (M + H) ⁺

< ¹³ C-NMR chemical shift δ (assigned carbon) of purified product 3>
159.5, 159.2 * 2, 158.6, 156.8: 2, 155.9, 155.8, 154.7, 146.8, 144.1, 141.7, 133.3, 132.8, 130.8, 130.5 * 2, 130.2 * 2, 130.0 * 2, 124.8, 121.0, 116.1 * 2, 116.0 * 2, 115.8, 115.5 * 2, 107.4 * 2, 105.9, 101.8, 101.7, 96.6, 90.6, 62.1, 57.4, 52.5, 48.8, 37.5

From the above results, the purified product 1 and the purified product 2 obtained were ε-viniferin (sample 2) represented by the following formula (1) and amperopsin A (sample 3) represented by the following formula (2), respectively. It was confirmed that. Moreover, the analysis result of the said refined | purified material 3 and Yoshiteru Oshima et al., "AMPELOPSINS A, B AND C, NEW OLIGOSTILBENES OF AMPELOPSIS BREVIPEDUNCULATA VAR. HANCEI", Tetrahedron, Vol. 46, No. 15, pp.5121-5126 As a result of comparing the mass spectrum analysis result of amperopsin C and ¹³ C-NMR chemical shift described in U.S.A., 1990, the obtained purified product 3 is amperopsin C represented by the following formula (3) (sample 4) It was confirmed that.

[Test Example 1] Tyrosinase activity inhibitory action test Each shrimp extract obtained in Production Example 1 (Samples 1 to 3), and ε-viniferin obtained in Production Example 2 (Sample 4) and amperopsin A (Sample 5) And amperopsin C (sample 6) was tested for tyrosinase activity inhibitory action as follows.

  In a 48-well plate, McClvaine buffer (pH 6.8) 0.2 mL, 0.3 mg / mL tyrosine solution 0.06 mL, 25% DMSO solution of sample (samples 1-4, see Table 2 below for sample concentration) 0.18 mL was added and allowed to stand at 37 ° C. for 10 minutes. To this, 0.02 mL of 800 units / mL tyrosinase solution was added, followed by reaction at 37 ° C. for 15 minutes. After completion of the reaction, the absorbance at a wavelength of 475 nm was measured. A blank test was conducted in the same manner. From the obtained measurement results, the tyrosinase activity inhibition rate (%) was calculated by the following formula.

Tyrosinase activity inhibition rate (%) = {1− (St−Sb) / (Ct−Cb)} × 100
In the formula, St is “absorbance when enzyme solution is added / sample solution is added”, Sb is “absorbance when enzyme solution is not added / sample solution is added”, and Ct is “absorbance when enzyme solution is added / sample solution is not added”. ", Cb indicates" absorbance when no enzyme solution is added / sample solution is not added ".
The results are shown in Table 2.

  As shown in Table 2, it was confirmed that the shrimp extract, ε-viniferin, amperopsin A and amperopsin C all have an excellent tyrosinase activity inhibitory action. Moreover, it was confirmed that the degree of the tyrosinase activity inhibitory action of amperopsin A and amperopsin C can be adjusted by the concentration.

[Test Example 2] Test for inhibiting melanin production on B16 melanoma cells Each shrimp extract obtained in Production Example 1 (Samples 1 to 3), and ε-viniferin (Sample 4) obtained in Production Example 2 and Amperopsin A About (sample 5) and amperopsin C (sample 6), the melanin production inhibitory effect with respect to B16 melanoma cell was tested as follows.

B16 melanoma cells were cultured using Dulbecco MEM containing 10% FBS, and then cells were collected by trypsin treatment. The collected cells were diluted with Dulbecco MEM containing 10% FBS and 1 mmol / L theophylline to a cell density of 25.0 × 10 ⁴ cells / mL, then seeded on a 48-well plate at 300 μL per well and cultured for 6 hours.

  After completion of the culture, 300 μL of a sample solution dissolved in Dulbecco's MEM containing 10% FBS and 1 mmol / L theophylline (samples 1 to 4, refer to Table 3 below for sample concentration) was added to each well and cultured for 4 days. After completion of the culture, the medium was removed from each well, 200 μL of 2 mol / L NaOH solution was added, the cells were disrupted with an ultrasonic crusher, and the absorbance at a wavelength of 475 nm was measured to obtain the amount of melanin produced.

  Moreover, in order to evaluate the melanin production inhibitory action per unit cell, after culture | cultivating similarly to the above, the culture solution was removed, and neutral red dissolved in Dulbecco's MEM containing 10% FBS at a final concentration of 0.05 mg / mL Was added to each well and cultured for 2.5 hours. After incubation, the neutral red solution was discarded, and 200 μL of ethanol / acetic acid solution (ethanol: acetic acid: water = 50: 1: 49) was added to each well to extract the dye. After extraction, the absorbance at a wavelength of 540 nm was measured.

  Furthermore, as a blank test, the absorbance at a wavelength of 475 nm and the absorbance at 540 nm were measured for cells cultured in the same manner as described above without adding a sample. From the obtained results, the melanin production inhibition rate (%) per unit cell was calculated by the following formula.

Melanin production inhibition rate (%) = {1− (B / D) / (A / C)} × 100
In the formula, A represents “absorbance at 475 nm when no sample is added”, B represents “absorbance at 475 nm when no sample is added”, C represents “absorbance at 540 nm when no sample is added”, and D represents “ The absorbance at 540 nm at the time of sample addition is expressed.
The results are shown in Table 3.

  As shown in Table 3, it was confirmed that the shrimp extract, ε-viniferin, amperopsin A and amperopsin C all have an excellent melanin production inhibitory action.

[Formulation Example 1]
An emulsion having the following composition was produced by a conventional method.
Shrimp 50% ethanol extract (Production Example 1) 0.01 g
Jojoba oil 4.0g
Twilight extract 0.1g
Olive oil 2.0g
Squalane 2.0g
Cetanol 2.0g
Glyceryl monostearate 2.0g
Polyoxyethylene cetyl ether (20E.O) 2.5g
Oleic acid polyoxyethylene sorbitan (20E.O) 2.0g
Stearyl glycyrrhetinate 0.1g
1,3-butylene glycol 3.0 g
Hinokitiol 0.15g
Fragrance 0.05g
Purified water remainder (total amount is 100 g)

[Formulation Example 2]
A cream having the following composition was produced by a conventional method.
ε-viniferin (Production Example 2) 0.05 g
Kujin extract 0.1g
Ogon Extract 0.1g
Liquid paraffin 5.0g
Salami beeswax 4.0g
Squalane 10.0g
Cetanol 3.0g
Lanolin 2.0g
Stearic acid 1.0g
Oleic acid polyoxyethylene sorbitan (20E.O) 1.5g
3.0 g glyceryl monostearate
Oil soluble licorice extract 0.1g
1,3-butylene glycol 6.0 g
1.5 g of methyl paraoxybenzoate
Fragrance 0.1g
Purified water remainder (total amount is 100 g)

[Composition Example 3]
A cream having the following composition was produced by a conventional method.
Ampelopsin A (Production Example 2) 0.05 g
Ages extract 0.1g
Walnut extract 0.1g
Polyethylene glycol monostearate 2.0g
Self-emulsifying glyceryl monostearate 5.0 g
Stearic acid 2.0g
Cetanol 2.0g
Squalane 12.0g
Macadamia nut oil 3.0g
0.2g of methylpolysiloxane
Fragrance 0.01g
Preservative (Methyl paraoxybenzoate) 0.15g
Oil soluble licorice extract 0.1g
1,3-butylene glycol 7.0 g
Xanthan gum 0.2g
Purified water remainder (total amount is 100 g)

[Formulation Example 4]
A serum having the following composition was produced by a conventional method.
Ampellopsin C (Production Example 2) 0.01 g
Chamomile extract 0.1g
Carrot extract 0.1g
Xanthan gum 0.3g
Hydroxyethylcellulose 0.1g
Carboxyvinyl polymer 0.1g
1,3-butylene glycol 4.0 g
0.1g dipotassium glycyrrhizinate
Glycerin 2.0g
Potassium hydroxide 0.25g
Fragrance 0.01g
Preservative (Methyl paraoxybenzoate) 0.15g
Ethanol 2.0g
Purified water remainder (total amount is 100 g)

  The whitening agent or skin cosmetic of the present invention is useful for the prevention, treatment or improvement of skin blackening, spots, freckles and the like due to excessive production and uneven accumulation of melanin.

Claims (6)

  A whitening agent comprising an extract from shrimp as an active ingredient.   The whitening agent according to claim 1, wherein the extract has a tyrosinase activity inhibitory action and / or a melanin production inhibitory action.   A whitening agent characterized by containing, as an active ingredient, one or more polyphenol compounds selected from the group consisting of ε-viniferin, amperopsin A and amperopsin C.   The whitening agent according to claim 3, wherein the polyphenol compound has a tyrosinase activity inhibitory action and / or a melanin production inhibitory action.   A skin cosmetic characterized by containing an extract from shrimp.   A skin cosmetic characterized by comprising one or more polyphenol compounds selected from the group consisting of ε-viniferin, amperopsin A and amperopsin C.